TVGNHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 11 Nov 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Tevogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (82): Smaller than most of the companies we track.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TVGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Mar 2026 | D. Boral Capital | Downgrade | Hold | — |
| 3 Mar 2026 | D. Boral Capital | Maintains | Buy | $5.00 → $2.00 |
| 20 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 11 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Mar 2025 | D. Boral Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TVGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Nov 2026, Tevogen, Inc. returned −77.7% against +12.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 96% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tevogen, Inc. has a market value of $100.6M and an enterprise value of $56.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$21.6M.
Free cash flow in the twelve months to 30 June 2026: −$11.6M.
Trailing P/E: 2.9×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Tevogen, Inc. employs 18 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tevogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Tevogen extended its loan agreement by two years, providing up to $28.6 million in borrowing capacity through May 2029. The extension complements the company’s existing ATM program.
Why it matters — The agreement extends Tevogen’s access to potential capital, alongside its ATM program.
Tevogen announced that it received written notice from Nasdaq on September 29, 2026, confirming the company has regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(B)(2)(A) for continued listing on the Nasdaq Global Market.
Why it matters — Regaining compliance removes the immediate risk of delisting and secures Tevogen's continued listing on the Nasdaq Global Market.
Tevogen Bio Holdings Inc. announced it will change its corporate name to Tevogen Inc., following approval by its Board of Directors. The company will operate under the new name effective immediately.
Why it matters — A name change can signal a shift in corporate identity or strategy, and shareholders will need to be aware of the new legal name for filings and communications.
Of the 1 analysts covering Tevogen, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tevogen, Inc. 16 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Nov 2026, Tevogen, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).
No analyst covering Tevogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVGN are extrapolating price history, which says nothing about the business.
Tevogen, Inc. returned -77.7% over the 12 months to 12 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Tevogen Inc. Common Stock is the equity security of Tevogen Inc., a clinical-stage specialty immunotherapy company focused on off-the-shelf precision T cell therapies.
The most recent item we track (GlobeNewsWire, 9 Nov 2026): "Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement". Tevogen extended its loan agreement by two years, providing up to $28.6 million in borrowing capacity through May 2029. The extension complements the company’s existing ATM program.
Tevogen Inc. Common Stock is the equity security of Tevogen Inc., a clinical-stage specialty immunotherapy company focused on off-the-shelf precision T cell therapies. The company develops treatments for infectious diseases, cancers, and other serious disorders, with current programs centered on viral infections, virus-related complications, and selected oncology and immune-related indications. Its platform combines cell therapy development with artificial intelligence tools that support drug discovery and therapeutic design. Tevogen’s pipeline includes product candidates in clinical and preclinical stages, reflecting a research-driven biotechnology business model centered on advancing targeted therapies. Headquartered in Warren, New Jersey, Tevogen Inc. operates as part of the broader healthcare and biotechnology market, where it contributes to the development of scalable immunotherapy solutions for unmet medical needs.
CEO Dr. Ryan H. Saadi M.D., M.P.H. · 18 employees · United States · https://tevogen.com
